In patients with renal insufficiency associated with increased hemoglobin levels and polycythemia, the possibilities of recombinant erythropoietin overdosing and disorders such as neoplasms and ...

Vanda Pharmaceuticals Inc.’s VGT-1849A, a selective antisense oligonucleotide (ASO)-based JAK2 inhibitor, has been awarded ...

Polycythemia vera is a slow growing blood cancer that happens in your bone marrow, the spongy tissue inside bones. It's usually caused by a gene mutation. Your bone marrow makes red blood cells ...

A panelist discusses how polycythemia vera (PV) is a rare myeloproliferative neoplasm (MPN) characterized by excessive red ...

THE course of polycythemia vera is complicated by hemorrhagic and thromboembolic phenomena of varying severity occurring in about a third of the cases. These complications have been ascribed to ...

Vanda Pharmaceuticals (VNDA)’ treatment of polycythemia vera was granted FDA orphan designation, according to a post to the agency’s ...

CATHERINE M. BROOME: Polycythemia vera is a blood disorder that is associated with an increase in production of the red blood cells. But white blood cells and platelets may also be affected.

(RTTNews) - Vanda Pharmaceuticals Inc. (VNDA) Friday announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for VGT-1849A, a selective antisense oligonucleotide ...

in patients with polycythemia vera (PV) were presented at the American Society of Hematology (ASH) Annual Meeting being held in San Diego, California. “Additional divesiran data presented at ASH ...

Articles on myeloproliferative neoplasms (MPNs) covered the debate over how early to use cytoreductive therapies instead of ...

Presentations at ASH include a quality-of-life evaluation for patients with polycythemia vera (PV) or essential thrombocythemia (ET) and treated with ropeginterferon alfa-2b compared to other best ...